Agenus Inc. (NASDAQ:AGEN - Get Free Report)'s stock price passed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $3.14 and traded as high as $5.05. Agenus shares last traded at $4.84, with a volume of 1,087,913 shares changing hands.
Analyst Ratings Changes
AGEN has been the subject of several research reports. B. Riley reissued a "buy" rating on shares of Agenus in a research report on Monday, April 21st. Robert W. Baird increased their price objective on shares of Agenus from $4.00 to $6.00 and gave the stock a "neutral" rating in a research report on Wednesday, June 4th. Wall Street Zen raised shares of Agenus from a "strong sell" rating to a "hold" rating in a research report on Thursday, May 22nd. Finally, HC Wainwright raised shares of Agenus from a "neutral" rating to a "buy" rating and set a $25.00 price objective for the company in a research report on Wednesday, June 4th. Five equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Hold" and a consensus target price of $14.00.
Get Our Latest Analysis on Agenus
Agenus Stock Up 7.6%
The company's fifty day moving average is $4.19 and its 200 day moving average is $3.20. The firm has a market cap of $162.60 million, a price-to-earnings ratio of -0.68 and a beta of 1.51.
Agenus (NASDAQ:AGEN - Get Free Report) last announced its quarterly earnings results on Monday, May 12th. The biotechnology company reported ($1.03) EPS for the quarter, beating analysts' consensus estimates of ($1.61) by $0.58. The firm had revenue of $24.07 million during the quarter, compared to analyst estimates of $26.38 million. On average, equities research analysts forecast that Agenus Inc. will post -12.55 EPS for the current fiscal year.
Institutional Trading of Agenus
A number of large investors have recently added to or reduced their stakes in AGEN. B. Riley Financial Inc. acquired a new stake in Agenus in the fourth quarter valued at $2,074,000. Siren L.L.C. acquired a new stake in Agenus in the first quarter valued at $752,000. AQR Capital Management LLC lifted its stake in Agenus by 3,080.3% in the first quarter. AQR Capital Management LLC now owns 441,486 shares of the biotechnology company's stock valued at $664,000 after acquiring an additional 427,604 shares during the last quarter. Gilead Sciences Inc. acquired a new stake in Agenus in the fourth quarter valued at $635,000. Finally, Strs Ohio acquired a new stake in shares of Agenus during the 1st quarter worth about $214,000. Institutional investors and hedge funds own 61.46% of the company's stock.
About Agenus
(
Get Free Report)
Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.
Read More
Before you consider Agenus, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Agenus wasn't on the list.
While Agenus currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
